Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effect of a proton pump inhibitor (omeprazole, Prilosec) on imatinib mesylate (Gleevec) pharmacokinetics in healthy volunteers (CSTI571BUS258)

Trial Profile

Effect of a proton pump inhibitor (omeprazole, Prilosec) on imatinib mesylate (Gleevec) pharmacokinetics in healthy volunteers (CSTI571BUS258)

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 08 Dec 2015

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Imatinib (Primary) ; Omeprazole
  • Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Dermatofibrosarcoma; Gastrointestinal stromal tumours; Malignant melanoma; Precursor cell lymphoblastic leukaemia-lymphoma; Prostate cancer
  • Focus Pharmacokinetics
  • Most Recent Events

    • 09 Sep 2009 Actual end date (1 Aug 2009) added as reported by ClinicalTrials.gov
    • 09 Sep 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov
    • 15 Feb 2008 The expected completion date for this trial is now 1 Dec 2008 as reported by ClinicalTrials.gov.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top